| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
9,230,000 |
| Market
Cap: |
3.60(M) |
| Last
Volume: |
426,351 |
Avg
Vol: |
422,918 |
| 52
Week Range: |
$0.39 - $0.39 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Cyclacel Pharmaceuticals is a clinical-stage biopharmaceutical company working to develop cancer medicines based on cell cycle, transcriptional regulation and mitosis control biology. The transcriptional regulation program is evaluating fadraciclib, a Cyclin Dependent Kinase 2/9 (CDK2/9) inhibitor, in solid tumors and hematological malignancies. The anti-mitotic program is evaluating CYC140, a Polo-Like-Kinase 1(PLK 1) inhibitor, in cancers. CDKs are a family of enzymes discovered as regulators of the cell cycle. PLK1 is a serine/threonine kinase with a central role in cell division, or the mitotic phase of the cell cycle, and is a regulator of the DNA damage checkpoint.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
7,956 |
| Total Buy Value |
$0 |
$0 |
$0 |
$26,374 |
| Total People Bought |
0 |
0 |
0 |
2 |
| Total Buy Transactions |
0 |
0 |
0 |
2 |
| Total Shares Sold |
0 |
194,628,820 |
194,628,820 |
194,628,820 |
| Total Sell Value |
$0 |
$5,507,996 |
$5,507,996 |
$5,507,996 |
| Total People Sold |
0 |
1 |
1 |
1 |
| Total Sell Transactions |
0 |
1 |
1 |
1 |
| End Date |
2025-03-30 |
2024-12-27 |
2024-06-28 |
2023-06-29 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Tan Kok Hui |
10% Owner |
– – • |
2025-04-29 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
250,000 |
|
- |
|
| Ho Kee Wee |
10% Owner |
– – • |
2025-04-29 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
250,000 |
|
- |
|
| Suria Sukses Engineering Sdn Bhd |
10% Owner |
– – • |
2025-04-29 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
250,000 |
|
- |
|
| Doris Wong Sing Ee |
Chief Executive OfficerOfficer |
• • • |
2025-02-26 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
194,628,820 |
|
- |
|
| Lazar David E. |
Interim CEO |
• – • |
2025-02-26 |
4 |
S |
$0.03 |
$5,507,996 |
D/D |
(194,628,820) |
0 |
|
- |
|
| Lazar David E. |
Interim CEO |
• – • |
2025-02-26 |
4 |
OE |
$0.00 |
$0 |
D/D |
194,628,820 |
194,628,820 |
|
- |
|
| Natan David |
Director |
– • – |
2025-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
100,000 |
100,000 |
|
- |
|
| Schwartz Brian |
Interim Chief Medical Officer |
• • – |
2024-01-29 |
4 |
A |
$0.00 |
$0 |
D/D |
12,500 |
15,205 |
|
- |
|
| Mcbarron Paul |
See Remarks |
• • – |
2023-12-21 |
4 |
B |
$3.32 |
$6,252 |
D/D |
1,886 |
33,378 |
2.81 |
- |
|
| Rombotis Spiro |
President and CEO |
• • – |
2023-12-21 |
4 |
B |
$3.32 |
$20,122 |
D/D |
6,070 |
68,658 |
2.81 |
- |
|
| Barker Sam L |
Director |
– • – |
2023-06-30 |
4 |
A |
$0.00 |
$0 |
D/D |
21,219 |
40,415 |
|
- |
|
| Spiegel Robert J. |
Director |
– • – |
2023-06-30 |
4 |
A |
$0.00 |
$0 |
D/D |
21,219 |
39,415 |
|
- |
|
| Henney Christopher S |
Director |
– • – |
2023-06-30 |
4 |
A |
$0.00 |
$0 |
D/D |
21,219 |
39,415 |
|
- |
|
| Schwartz Brian |
Director |
– • – |
2023-06-30 |
4 |
A |
$0.00 |
$0 |
D/D |
21,219 |
40,602 |
|
- |
|
| Walker Karin L |
Director |
– • – |
2023-06-30 |
4 |
A |
$0.00 |
$0 |
D/D |
21,219 |
40,602 |
|
- |
|
| Ferguson Kenneth M. |
Director |
– • – |
2023-06-30 |
4 |
A |
$0.00 |
$0 |
D/D |
21,219 |
44,952 |
|
- |
|
| Rombotis Spiro |
President and CEO |
• • – |
2023-01-31 |
4 |
A |
$0.00 |
$0 |
D/D |
57,600 |
62,588 |
|
- |
|
| Kirschbaum Mark |
Chief Medical Officer |
• – – |
2023-01-31 |
4 |
A |
$0.00 |
$0 |
D/D |
31,200 |
31,200 |
|
- |
|
| Mcbarron Paul |
See Remarks |
• • – |
2023-01-31 |
4 |
A |
$0.00 |
$0 |
D/D |
31,200 |
31,492 |
|
- |
|
| Henney Christopher S |
Director |
– • – |
2022-06-14 |
4 |
A |
$0.00 |
$0 |
D/D |
15,822 |
18,196 |
|
- |
|
| Spiegel Robert J. |
Director |
– • – |
2022-06-14 |
4 |
A |
$0.00 |
$0 |
D/D |
15,822 |
18,196 |
|
- |
|
| Walker Karin L |
Director |
– • – |
2022-06-14 |
4 |
A |
$0.00 |
$0 |
D/D |
15,822 |
19,383 |
|
- |
|
| Ferguson Kenneth M. |
Director |
– • – |
2022-06-14 |
4 |
A |
$0.00 |
$0 |
D/D |
27,733 |
27,733 |
|
- |
|
| Schwartz Brian |
Director |
– • – |
2022-06-14 |
4 |
A |
$0.00 |
$0 |
D/D |
15,822 |
19,383 |
|
- |
|
| Sems Lloyd |
Director |
– • – |
2022-06-14 |
4 |
A |
$0.00 |
$0 |
D/D |
15,822 |
18,196 |
|
- |
|
38 Records found
|
|
Page 1 of 2 |
|
|
